Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Free Cash Flow: 2010-2025

Historic Free Cash Flow for Ligand Pharmaceuticals (LGND) over the last 15 years, with Sep 2025 value amounting to $13.1 million.

  • Ligand Pharmaceuticals' Free Cash Flow fell 64.21% to $13.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $104.7 million, marking a year-over-year increase of 8449.92%. This contributed to the annual value of $95.2 million for FY2024, which is 106.76% up from last year.
  • As of Q3 2025, Ligand Pharmaceuticals' Free Cash Flow stood at $13.1 million, which was down 16.11% from $15.6 million recorded in Q2 2025.
  • In the past 5 years, Ligand Pharmaceuticals' Free Cash Flow registered a high of $101.7 million during Q4 2024, and its lowest value of -$61.6 million during Q2 2024.
  • In the last 3 years, Ligand Pharmaceuticals' Free Cash Flow had a median value of $13.1 million in 2025 and averaged $13.1 million.
  • As far as peak fluctuations go, Ligand Pharmaceuticals' Free Cash Flow surged by 2,428.18% in 2021, and later slumped by 21,507.37% in 2024.
  • Ligand Pharmaceuticals' Free Cash Flow (Quarterly) stood at $25.4 million in 2021, then surged by 101.76% to $51.3 million in 2022, then tumbled by 85.10% to $7.6 million in 2023, then soared by 1,229.11% to $101.7 million in 2024, then crashed by 64.21% to $13.1 million in 2025.
  • Its Free Cash Flow was $13.1 million in Q3 2025, compared to $15.6 million in Q2 2025 and -$25.7 million in Q1 2025.